dr. al-sawaf on updated pfs data with venetoclax plus obinutuzumab in cll
Published 4 years ago • 355 plays • Length 1:46Download video MP4
Download video MP3
Similar videos
-
0:56
dr. al-sawaf on continual mrd assessment after venetoclax/obinutuzumab in cll
-
1:42
dr. al-sawaf on new safety signals with venetoclax/obinutuzumab in the cll14 trial
-
1:16
dr. al-sawaf on fixed-duration versus continuous treatment in cll
-
1:52
dr. al-sawaf on testing for ckt in cll
-
5:54
cll14: venetoclax plus obinutuzumab for cll
-
8:46
new data supports long term efficacy of venetoclax-obinutuzumab for cll patients
-
1:02
dr. gerson on venetoclax/obinutuzumab combination in cll
-
2:00
venetoclax plus rituximab or obinutuzumab in cll after allohct
-
3:50
othman al-sawaf, md, on potential safety concerns associated with venetoclax combinations
-
1:24
venetoclax plus obinutuzumab in ckt cll: analysis from the cll14 trial
-
1:01
dr. abedin on the role of venetoclax plus obinutuzumab in cll
-
1:13
dr. flinn on next steps with venetoclax plus obinutuzumab in cll
-
5:12
cll14: venetoclax plus obinutuzumab in untreated cll
-
0:59
5-year follow-up results of cll14: obinutuzumab venetoclax vs obinutuzumab chlorambucil in cll
-
20:43
venetoclax resistance: mechanisms and treatment options
-
24:09
update on venetoclax for cll
-
10:24
fixed-duration therapy with venetoclax-obinutuzumab in frontline cll
-
1:03
dr. flinn on toxicities with venetoclax plus obinutuzumab in cll
-
5:09
othman al-sawaf, md, on the role of mrd in the management of cll as a result of data from ash 2020